[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335130-105":59,"doc-detail-335130-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","elucidating-the-pan-oncologic-landscape-of-s100a9-prognostic-and-therapeutic-corollaries-from-an-integrative-bioinformatics-and-mendelian-randomization-analysis","Elucidating the pan-oncologic landscape of S100A9 - prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis","","The calcium-binding protein S100A9 is examined as a biomolecular actor across cancer types through integrative bioinformatics and Mendelian randomization. Using public cancer genomics resources such as TCGA, the study performs differential expression, mutational burden, protein interaction network, and survival analyses. It maps heterogeneous S100A9 expression across malignancies, links expression with prognosis and with tumor mutational burden and microsatellite instability, and evaluates DNA methylation and immune infiltration patterns across selected tumors. The results support S100A9 as a prognostic biomarker and candidate therapeutic target.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/elucidating-the-pan-oncologic-landscape-of-s100a9-prognostic-and-therapeutic-corollaries-from-an-integrative-bioinformatics-and-mendelian-randomization-analysis/335130/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/elucidating-the-pan-oncologic-landscape-of-s100a9-prognostic-and-therapeutic-corollaries-from-an-integrative-bioinformatics-and-mendelian-randomization-analysis/335130.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What analyses were used to evaluate S100A9 in cancers?","Question",{"text":112,"@type":113},"The study applies differential expression analysis, mutational burden assessment, protein interaction network analysis, and survival analysis using public cancer genomics databases such as TCGA.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does S100A9 expression relate to prognosis across tumor types?",{"text":117,"@type":113},"S100A9 expression correlates variably with patient outcomes, with associations differing by cancer type rather than showing a single uniform prognostic direction.",{"name":119,"@type":110,"acceptedAnswer":120},"What links were found between S100A9 and tumor mutational burden or microsatellite instability?",{"text":121,"@type":113},"S100A9 expression is closely associated with tumor mutational burden (TMB) and microsatellite instability (MSI) in nine cancer types.",{"name":123,"@type":110,"acceptedAnswer":124},"How is S100A9 associated with immune cell infiltration?",{"text":125,"@type":113},"In six selected tumors, S100A9 shows a negative correlation with infiltration of most immune cells, while showing positive correlations with neutrophils, M1 macrophages, and activated NK cells, indicating a complex interplay with the tumor immune environment.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335130,1790199730,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nElucidating the pan‑oncologic landscape ofS100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis  \nYingying Chen1, Zixuan Wu2 & Xingxing Yi1*  \nThe calcium‑binding protein S100A9 has emerged as a pivotal biomolecular actor in oncology, implicated in numerous malignancies. This comprehensive bioinformatics study transcends traditional boundaries, investigating the prognostic and therapeutic potential ofS100A9 across diverse neoplastic entities. Leveraging a wide array of bioinformatics tools and publicly available cancer genomics databases, such as TCGA, we systematically examined the S100A9 gene. Our approach included differential expression analysis, mutational burden assessment, protein interaction networks, and survival analysis. This robust computational framework provided a high‑resolution view ofS100A9’s role in cancer biology. The study meticulously explored S100A9’s oncogenic facets, incorporating comprehensive analyses of its relationship with prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration across various tumor types. This study presents a panoramic view ofS100A9 expression across a spectrum of human cancers, revealing a heterogeneous expression landscape. Elevated S100A9 expression was detected in malignancies such as BLCA (Bladder Urothelial Carcinoma), CESC (Cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD (Colon adenocarcinoma), ESCA (Esophageal carcinoma), and GBM (Glioblastoma multiforme), while reduced expression was noted in BRCA (Breast invasive carcinoma), HNSC (Head and Neck squamous cell carcinoma), and KICH (Kidney Chromophobe) .  \nThis disparate expression pattern suggests that S100A9’s role in cancer biology is multifaceted and context‑dependent. Prognostically, S100A9 expression correlates variably with patient outcomes across different cancer types. Furthermore, its expression is intricately associated with TMB and MSI in nine cancer types. Detailed examination of six selected tumors—BRCA, CESC, KIRC (Kidney renal clear cell carcinoma), LUSC (Lung squamous cell carcinoma), SKCM (Skin Cutaneous Melanoma); STAD (Stomach adenocarcinoma)—revealed a negative correlation ofS100A9 expression with the infiltration of most immune cells, but a positive correlation with neutrophils, M1 macrophages, and activated NK cells, highlighting the complex interplay between S100A9 and the tumor immune environment. This bioinformatics synthesis posits S100A9 as a significant player in cancer progression, offering valuable prognostic insights. The data underscore the utility of S100A9 as a prognostic biomarker and its potential as a therapeutic target. The therapeutic implications are profound, suggesting that modulation ofS100A9 activity could significantly impact cancer management strategies.  \nKeywords S100A9, Cancer heterogeneity, Prognosis, Immune infiltration, Tumor mutational burden, Microsatellite instability  \n1The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, Hunan, China. 2Hunan University  \nof Chinese Medicine, Changsha 410128, China.* email: [1037603220@qq.com](1037603220@qq.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nAbbreviations  \nS100A9 S100 calcium binding protein A9 GO Gene ontology  \nKEGG Kyoto Encyclopedia of Genes and Genomes  \nTME Tumor microenvironment  \nTMB Tumor mutational burden  \nDSS Disease-specific survival  \nHR Hazard ratios  \nPPI Protein–protein interaction  \nCR Complete response  \nPD Progressing disease  \nTCGA The Cancer Genome Atlas GEO Gene Expression Omnibus GSEA Gene set enrichment analysis MSI Microsatellite instability  \nOS Overall survival  \nCI Confidence intervals  \nTIICs Tumor-infiltrating immune cells PFs Progression-free survival  \nPR Partial response  \nSD Stable illness  \nThe rel","cbCaim33DKqPE93q","https://ap.wps.com/l/cbCaim33DKqPE93q","pdf",8476314,"English","# S100A9 oncologic landscape and study aim\n## Bioinformatics framework and public datasets\n## Expression patterns and prognostic associations\n## Tumor mutational burden, MSI, and DNA methylation\n## Immune infiltration and tumor microenvironment interactions","[{\"question\":\"What analyses were used to evaluate S100A9 in cancers?\",\"answer\":\"The study applies differential expression analysis, mutational burden assessment, protein interaction network analysis, and survival analysis using public cancer genomics databases such as TCGA.\"},{\"question\":\"How does S100A9 expression relate to prognosis across tumor types?\",\"answer\":\"S100A9 expression correlates variably with patient outcomes, with associations differing by cancer type rather than showing a single uniform prognostic direction.\"},{\"question\":\"What links were found between S100A9 and tumor mutational burden or microsatellite instability?\",\"answer\":\"S100A9 expression is closely associated with tumor mutational burden (TMB) and microsatellite instability (MSI) in nine cancer types.\"},{\"question\":\"How is S100A9 associated with immune cell infiltration?\",\"answer\":\"In six selected tumors, S100A9 shows a negative correlation with infiltration of most immune cells, while showing positive correlations with neutrophils, M1 macrophages, and activated NK cells, indicating a complex interplay with the tumor immune environment.\"}]","Elucidating the pan-oncologic landscape of S100A9 - prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis | PDF",1790009757,48]